| Identification | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Hydroxocobalamin | ||||||||||||||||||||||||||
| Accession Number | DB00200 (APRD01022) | ||||||||||||||||||||||||||
| Type | small molecule | ||||||||||||||||||||||||||
| Groups | approved | ||||||||||||||||||||||||||
| Description | Injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. [PubChem] |
||||||||||||||||||||||||||
| Structure |
Download: MOL | SDF | SMILES | InChI Display: 2D Structure | 3D Structure |
||||||||||||||||||||||||||
| Synonyms |
|
||||||||||||||||||||||||||
| Salts | Not Available | ||||||||||||||||||||||||||
| Brand names |
|
||||||||||||||||||||||||||
| Brand mixtures |
|
||||||||||||||||||||||||||
| Categories |
|
||||||||||||||||||||||||||
| CAS number | 13422-51-0 | ||||||||||||||||||||||||||
| Weight |
Average: 1346.3551 Monoisotopic: 1345.567070949 |
||||||||||||||||||||||||||
| Chemical Formula | C62H89CoN13O15P | ||||||||||||||||||||||||||
| InChI Key | InChIKey=YOZNUFWCRFCGIH-WZHZPDAFSA-K | ||||||||||||||||||||||||||
| InChI |
InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+3;/p-3/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1
Plain Text
|
||||||||||||||||||||||||||
| IUPAC Name | |||||||||||||||||||||||||||
| SMILES |
[H]O[Co+]N1\C2=C(C)/C3=N/C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]1([H])[C@H](CC(=O)N)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@H](O[C@@H]1CO)N1C=NC2=CC(C)=C(C)C=C12)[C@@](C)(CC(N)=O)[C@@H]5CCC(=O)N)\[C@@](C)(CC(=O)N)[C@@H]4CCC(=O)N)/C(C)(C)[C@@H]3CCC(=O)N
Plain Text
|
||||||||||||||||||||||||||
| Mass Spec | Not Available | ||||||||||||||||||||||||||
| Taxonomy | |||||||||||||||||||||||||||
| Kingdom | Not Available | ||||||||||||||||||||||||||
| Classes | Not Available | ||||||||||||||||||||||||||
| Substructures | Not Available | ||||||||||||||||||||||||||
| Pharmacology | |||||||||||||||||||||||||||
| Indication | For treatment of pernicious anemia and the prevention and treatment of vitamin B12 deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets. Also for the treatment of known or suspected cyanide poisoning. | ||||||||||||||||||||||||||
| Pharmacodynamics | Hydroxocobalamin is a synthetic, injectable form of Vitamin B12. Hydroxocobalamin is actually a precursor of two cofactors or vitamins (Vitamin B12 and Methylcobalamin) which are involved in various biological systems in man. Vitamin B12 is required for the conversion of methylmalonate to succinate. Deficiency of this enzyme could therefore interfere with the production of lipoprotein in myelin sheath tissue and so give rise to neurological lesions. The second cofactor, Methylcobalamin, is necessary for the conversion of homocysteine to methionine which is essential for the metabolism of folic acid. Deficiency of tetrahydrafolate leads to reduced synthesis of thymidylate resulting in reduced synthesis of DNA which is essential for cell maturation. Vitamin B12 is also concerned in the maintenance of sulphydryl groups in reduced form, deficiency leading to decreased amounts of reduced SH content of erythrocytes and liver cells. Overall, vitamin B12 acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis. It is necessary for growth, cell replication, hematopoiesis, and nucleoprotein as well as myelin synthesis. This is largely due to its effects on metabolism of methionine folic acid, and malonic acid. | ||||||||||||||||||||||||||
| Mechanism of action | Vitamin B12 exists in four major forms referred to collectively as cobalamins; deoxyadenosylcobalamin, methylcobalamin, hydroxocobalamin, and cyanocobalamin. Two of these, methylcobalamin and 5-deoxyadenosyl cobalamin, are primarily used by the body. Methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells. | ||||||||||||||||||||||||||
| Absorption | Readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Vitamin B12 is absorbed in the lower half of the ileum. | ||||||||||||||||||||||||||
| Volume of distribution | Not Available | ||||||||||||||||||||||||||
| Protein binding | Very high (90%). Cobalamins are extensively bound to two specific plasma proteins called transcobalamin 1 and 2; 70% to transcobalamin 1, 5% to transcobalamin 2. | ||||||||||||||||||||||||||
| Metabolism | Primarily hepatic. Cobalamins are absorbed in the ileum and stored in the liver. They continuously undergo enterohepatic recycling via secretion in the bile. Part of a dose is excreted in the urine, most of it in the first 8 hours. | ||||||||||||||||||||||||||
| Route of elimination | Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine. | ||||||||||||||||||||||||||
| Half life | Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration) | ||||||||||||||||||||||||||
| Clearance | Not Available | ||||||||||||||||||||||||||
| Toxicity | Not Available | ||||||||||||||||||||||||||
| Affected organisms |
|
||||||||||||||||||||||||||
| Pathways | Not Available | ||||||||||||||||||||||||||
| Pharmacoeconomics | |||||||||||||||||||||||||||
| Manufacturers |
|
||||||||||||||||||||||||||
| Packagers |
|
||||||||||||||||||||||||||
| Dosage forms |
|
||||||||||||||||||||||||||
| Prices |
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational
purposes only.
|
||||||||||||||||||||||||||
| Patents |
|
||||||||||||||||||||||||||
| Properties | |||||||||||||||||||||||||||
| State | solid | ||||||||||||||||||||||||||
| Experimental Properties | Not Available | ||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||
| References | |||||||||||||||||||||||||||
| Synthesis Reference | Not Available | ||||||||||||||||||||||||||
| General Reference | |||||||||||||||||||||||||||
| External Links |
|
||||||||||||||||||||||||||
| ATC Codes |
|
||||||||||||||||||||||||||
| AHFS Codes |
|
||||||||||||||||||||||||||
| PDB Entries | Not Available | ||||||||||||||||||||||||||
| FDA label | Not Available | ||||||||||||||||||||||||||
| MSDS | show (73.6 KB) | ||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||
| Drug Interactions | Searched, but no interactions found. | ||||||||||||||||||||||||||
| Food Interactions | Not Available | ||||||||||||||||||||||||||
| Targets |
|---|
|
Pharmacological action: yes
Actions: cofactor Organism class: human UniProt ID: Q99707 ![]() Gene: MTR ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
2. Methylmalonyl-CoA mutase, mitochondrial Pharmacological action: yesActions: cofactor Involved in the degradation of several amino acids, odd- chain fatty acids and cholesterol via propionyl-CoA to the tricarboxylic acid cycle. MCM has different functions in other species Organism class: humanUniProt ID: P22033 ![]() Gene: MUT ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
3. Methionine synthase reductase, mitochondrial Pharmacological action: unknownActions: other Involved in the reductive regeneration of cob(I)alamin cofactor required for the maintenance of methionine synthase in a functional state Organism class: humanUniProt ID: Q9UBK8 ![]() Gene: MTRR ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References: 4. Methylmalonic aciduria type A protein, mitochondrial Pharmacological action: unknownActions: other/unknown May be involved in the transport of cobalamin (Cbl) into mitochondria for the final steps of adenosylcobalamin (AdoCbl) synthesis Organism class: humanUniProt ID: Q8IVH4 ![]() Gene: MMAA ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
Pharmacological action: unknown
Actions: other Vitamin B12-binding protein. Transports cobalamin into cells Organism class: humanUniProt ID: P20061 ![]() Gene: TCN1 ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
Pharmacological action: unknown
Actions: other Necessary for efficient absorption of vitamin B12. May direct the production of trunk mesoderm during development by modulating a bone morphogenetic protein (BMP) signaling pathway in the underlying visceral endoderm Organism class: humanUniProt ID: Q9BXJ7 ![]() Gene: AMN ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
7. Cubilin Pharmacological action: unknownActions: other Cotransporter which plays a role in lipoprotein, vitamin and iron metabolism, by facilitating their uptake. Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, and the GIF-cobalamin complex. The binding of all ligands required calcium. Serves as important transporter in several absorptive epithelia, including intestine, renal proximal tubules and embryonic yolk sac. Interaction with LRP2 mediates its trafficking throughout vesicles and facilitates the uptake of specific ligands like GC, hemoglobin, ALB, TF and SCGB1A1. Interaction with AMN controls its trafficking to the plasma membrane and facilitates endocytosis of ligands. May play an important role in the development of the peri-implantation embryo through internalization of APOA1 and cholesterol. Binds to LGALS3 at the maternal-fetal interface Organism class: humanUniProt ID: O60494 ![]() Gene: CUBN ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
8. Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial Pharmacological action: unknownActions: other Organism class: human UniProt ID: Q96EY8 ![]() Gene: MMAB ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References: 9. Methylmalonic aciduria and homocystinuria type C protein Pharmacological action: unknownActions: other/unknown May be involved in the binding and intracellular trafficking of cobalamin (vitamin B12) Organism class: humanUniProt ID: Q9Y4U1 ![]() Gene: MMACHC ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
|
| Carriers |
|---|
|
Actions: substrate
Primary vitamin B12-binding and transport protein. Delivers cobalamin to cells UniProt ID: P20062![]() Gene: TCN2 ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
|
| Comments |
|---|